HIV RNA testing in the context of nonoccupational postexposure prophylaxis

Journal of Infectious Diseases

Volumn 190, Issue 3, 2004, Pages 598-604

  Roland, Michelle E ^a,c   Elbeik, Tarek A ^a   Kahn, James O ^a   Bamberger, Joshua D ^d   Coates, Thomas J ^b   Krone, Melissa R ^b   Katz, Mitchell H ^a,b   Busch, Michael P ^e   Martin, Jeffrey N ^a,b,c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Public Health ^*  (United States)

^e BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INFECTION PREVENTION; INTERMETHOD COMPARISON; NONHUMAN; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SEROLOGY;

ANTI-HIV AGENTS; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; HIV INFECTIONS; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASES, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TRANSCRIPTION, GENETIC;

EID: 3242802876     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421278     Document Type: Article

References (29)

1. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-90.
2. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707-14.
3. Kunches LM, Meehan TM, Boutwell RC, McGuire JF. Survey of non-occupational hiv postexposure prophylaxis in hospital emergency departments. J Acquir Immune Defic Syndr 2001; 26:263-5.
4. Correll P, Smith D, Hendry O, Grulich A. Non occupational HIV post exposure prophylaxis (PEP) in Australia [abstract WePeC4420]. In: The XIII International AIDS Conference. Durban, South Africa. Stockholm: International AIDS Society, 2000.
5. Rabaud C, Bevilacqua S, Beguinot I, et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32:1494-5.
6. Wiebe ER, Comay SE, McGregor M, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. Cmaj 2000; 162:641-5.
7. Busch M, Satten G. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. AM J Med 1997; 102:117-24.
8. Fiebig EW, Rawal BD, Garrett PE, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9.
9. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion 2000; 40:1157-60.
10. Stramer SL. US NAT yield: where are we after 2 years? Transfus Med 2002; 12:243-53.
11. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165-8.
12. Collins M, Irvine B, Tyner D, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/mL. Nucleic Acids Res 1997; 25:2979-84.
13. Kern D, Collins M, Fultz T, et al. An enhanced-sensitivity branced-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34:3196-3202.
14. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998; 36:2964-9.
15. McDonough S, Giachetti C, Yang Y. High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Infusion Ther Transfusion Med 1998; 25:164-9.
16. Nelson NC, Cheikh AB, Matsuda E, Becker MM. Simultaneous detection of multiple nucleic acid targets in a homogeneous format. Biochemistry 1996; 35:8429-38.
17. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002; 40:2408-19.
18. Sackett DL HR, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston: Little, Brown, 1991.
19. Pilcher CD, McPherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002; 288:216-21.
20. McFarland W. 2001 HIV Consensus Meeting report. In: San Francisco Department of Health HIV Consensus Meeting. San Francisco, CA, 2001. San Francisco: Department of Public Health, 2001:2, 12-15.
21. Blumer S, Schalla W, Hearn T, Fehd R. Evaluation of laboratory performance in determining HIV-1 viral RNA levels present in CDC performance evaluation samples. In: In abstracts of the Conference on the Laboratory Science of HIV, 1998. Available at: http://www.phppo .cdc.gov/mlp/pdf/labhiv/ AllPosters.pdf. Accessed: 2 July 2004.
22. Erice A, Brambilla D, Bremer J, et al. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000; 38:2837-45.
23. Gale H. Evaluation of the quantiplex human immunodeficiency virus type 1 RNA 3.0 assay in a tertiary-care center. Clin Diagn Lab Immunol 2000; 7:122-4.
24. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25-9.
25. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-29.
26. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999; 130:37-9.
27. More D, O'Brien K, Walter E. Utility of an HIV-1 RNA assay in the diagnosis of acute retroviral syndrome. South Med J 2000; 93:1004-6.
28. de Mendoza C, Holguin A, Soriano V. False positives for HIV using commercial viral load quantification assays. AIDS 1998; 12:2076-7.
29. Brambilla D, Granger S, Jennings C, Bremer J. Rates of false-positive results on quantitative HIV RNA assays [abstract 236]. In: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.